Hydroxychloroquine early in pregnancy and risk of birth defects: absence of evidence is not the same as evidence of absence - 30/04/21
Doi : 10.1016/j.ajog.2020.12.1219
Krista F. Huybrechts, MS, PhD 
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, 1620 Tremont St., Suite 3030, Boston, MA 02120
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA
Brian T. Bateman, MD, MS
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Sonia Hernandez-Diaz, MD, DrPH
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA
Le texte complet de cet article est disponible en PDF.
| K.F.H. reports being an investigator on grants to Brigham and Women’s Hospital from Eli Lilly and Company and GlaxoSmithKline for unrelated studies. B.T.B. reports being an investigator on grants to Brigham and Women’s Hospital from Eli Lilly and Company, Baxalta, GlaxoSmithKline, and Pacira Pharmaceutical Inc for unrelated studies; received personal fees from Aetion Inc and from the Alosa Foundation outside the submitted work; and served on an expert panel for a postpartum hemorrhage quality improvement project that was conducted by the Association of Women’s Health, Obstetric, and Neonatal Nurses and funded by a grant from Merck for Mothers. S.H.-D. reports being an investigator on grants to her institution from Eli Lilly and Company and GlaxoSmithKline for unrelated studies; receiving personal fees from UCB outside the submitted work; and having served as an epidemiologist with the North American Antiepileptic Drug Pregnancy Registry, which is funded by multiple companies. |
|
| The original study was supported by internal funds of the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School. |
© 2021
Elsevier Inc. Tous droits réservés.
Vol 224 - N° 5
P. 549-550 - mai 2021 Retour au numéro
Article précédent
- Hydroxychloroquine early in pregnancy and risk of birth defects: don’t throw out the baby with the bathwater
- Bonnie L. Bermas, Christina Chambers
- Coronavirus disease 2019 in pregnancy was associated with maternal morbidity and preterm birth
- Rasha A. Al-Lami, Ali M. Alrammahi, Ammar M.A. Algburi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?